Passkey
Passkey Therapeutics is a Cambridge-based biotech with the Locksmith® computational genetics platform that maps synergistic combinations of approved drugs, partnering with pharmaceutical and biotech companies to advance clinic-ready combination therapies for complex diseases.
- Company typePrivate
- Founded2022
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Passkey does
Passkey Therapeutics is a Cambridge, Massachusetts-based computational biotechnology company founded in 2022 that has developed the Locksmith® platform, a computational genetics system designed to map synergistic pharmacology between existing approved drugs. The platform analyzes 4,000 approved drugs, 10,000 biological pathways, and 600 billion genetic variants to identify therapeutic combinations for complex diseases, with the stated goal of bypassing traditional preclinical development by leveraging drugs with established human safety profiles. Passkey is preparing for clinical trials in four indications and presents the platform as a tool for pharmaceutical and biotech partners to expand the use of their existing drug portfolios.
The company operates a B2B partnership model targeting pharmaceutical and biotech companies through a tiered offering: Subscribe (annual access fee for Locksmith predictions mapped against partner assets), Unlock (licensing of clinic-ready combinations of approved drugs), and Advance (direct-to-clinical validation partnerships). Revenue is generated from three streams: recurring subscription access fees, licensing/royalty arrangements on combinations, and downstream outcome-based payments tied to clinical and commercial success.
The company is co-founded by CEO Bruce Beutel, whose prior roles include R&D leadership at Abbott Laboratories and Merck and executive positions at SQZ Biotechnologies and Dewpoint Therapeutics, and CTO Will Chen, a former Distinguished Investigator at Biogen with academic roles at Harvard Medical School and MIT focused on systems pharmacology. Dr. Mandeep Kaur joined as Chief Medical Officer from Amgen, where she was SVP of Global Medical Affairs following the Horizon Therapeutics acquisition. Passkey is privately held and venture-backed by Breakout Ventures (lead), Alexandria Venture Investments, Bison Ventures, GRIDS Capital, Innovation Endeavors, Wireframe Ventures, and Spymed Ventures, having closed a $20M financing in October 2024.
Passkey firmographics
Firmographics- Name
- Passkey
- Legal name
- Passkey Therapeutics, Inc.
- Website
- https://passkeytx.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Passkey Therapeutics is a Cambridge-based biotech with the Locksmith® computational genetics platform that maps synergistic combinations of approved drugs, partnering with pharmaceutical and biotech companies to advance clinic-ready combination therapies for complex diseases.
- Ownership category
- akta.pro rank
Passkey industry classification
Industry- Product category
- Computational Drug Discovery
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)
- akta.pro secondary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Passkey is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Passkey business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Access Fee Partnership: Pharmaceutical partners pay an access fee to view Locksmith predictions mapped against their existing drug assets. Enables partners to identify synergistic combinations within their portfolio.
- Clinic-Ready Combination Licensing: Partners unlock access to combinations of drugs with proven safety in humans across disease areas. Revenue generated from licensing these combinations for clinical advancement.
- Clinical and Commercial Outcomes: Downstream financial arrangements based on clinical and commercial success of partnered combinations. Alignment model where Passkey and partners succeed together.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Partner access model - access fee for platform predictions |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Passkey product offering
Product offeringCore offering
Passkey Therapeutics offers the Locksmith® computational platform, which maps synergistic pharmacology across 4,000 approved drugs, 10,000 biological pathways, and 600 billion genetic variants to identify therapeutic drug combinations for complex diseases. The company partners with pharmaceutical and biotech companies through Subscribe, Unlock, and Advance engagement pathways, enabling combinations of approved drugs to bypass traditional preclinical development and proceed directly to human proof of concept. Passkey is preparing for clinical trials in 4 indications.
Product overview
Passkey Therapeutics offers the Locksmith® platform as its core computational product for drug discovery. The platform identifies synergistic drug combinations by analyzing genetic variants, approved drugs, and biological pathways. Locksmith maps synergistic potential hidden in existing drugs, enabling combinations to bypass traditional preclinical development and proceed directly to human proof of concept using approved and late-stage drugs. The company partners with pharmaceutical companies to apply the platform to their existing drug portfolios and is preparing for clinical trials in 4 indications.
Differentiator
Problem solved
Functional benefit
Brands
- Locksmith®: Computational platform that maps synergistic pharmacology to identify therapeutic synergies between existing approved drugs, enabling combinations to bypass traditional preclinical development.
Products and services
- Locksmith® Platform A computational platform that maps synergistic pharmacology using human genetics, biology, and pharmacology data to identify therapeutic synergies between existing approved drugs, enabling drug combinations to proceed directly to human proof of concept without traditional preclinical development. The platform is offered to pharmaceutical and biotech partners under a tiered partnership model (Subscribe, Unlock, Advance) and is being applied to 4 indications in clinical trial preparation.
Quantifiable outcome
- Combinations can bypass traditional preclinical development entirely and proceed directly to human proof of concept using approved and late stage drugs
- +2 more outcomes
Companies that use Passkey
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Passkey technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature1 record
Passkey partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights5 records
Passkey competitors and assessment
Company assessmentDirect peers
- Insitro: Machine learning-driven drug discovery platform integrating data generation and predictive modeling. Operates a similar platform-pharma partnership model targeting complex diseases with high unmet need.
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with computational models to identify novel therapeutics. Directly comparable as a platform-based drug discovery company partnering with pharma to accelerate therapeutic development.
- Schrödinger: Computational chemistry and drug discovery platform serving pharma clients with physics-based modeling. Direct peer in computational drug discovery with established pharma partnership revenues.
- Exscientia: AI-driven precision medicine company designing novel drug candidates via its platform. Comparable platform-partnership model with multiple pharma collaborations and clinical-stage programs.
- Atomwise: AI-driven small molecule drug design platform partnering with pharma to accelerate hit identification. Closely comparable as a platform-first computational drug discovery company with pharma partnership economics.
- Isomorphic Labs: Alphabet-backed AI drug discovery company applying computational biology to identify novel therapeutics. Comparable as a deep-pocketed platform peer using computation to redesign and accelerate drug discovery.
- Healx: AI-driven drug repurposing company focused on rare diseases. Highly comparable business model: uses computation to identify therapeutic applications of existing drugs, bypassing traditional preclinical timelines.
Emerging players
- Dewpoint Therapeutics: Biomolecular condensate-focused drug discovery platform. Both founders (Beutel, Chen) previously held leadership roles at Dewpoint, making it a closely related emerging platform peer with similar pharma-partnership orientation.
- Lantern Pharma: AI-driven oncology company developing drug combinations using computational approaches. Comparable as a smaller-cap AI biotech pursuing drug combinations and repositioning strategies with pharma partners.
Broad incumbents
- Owkin: AI biotech applying machine learning to drug discovery and clinical development across multiple therapeutic areas. Broader incumbent platform peer using AI/ML across the drug development value chain with pharma partnerships.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Passkey social profiles
Digital presencePasskey financial estimates
Financial estimateRevenue estimate
Valuation estimate
Passkey leadership team
Management profileNumber of profiles
Profiles5 records
Passkey funding detail
Funding detailFunding overview
Funding rounds1 record
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Passkey M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Passkey
What does Passkey do?
Passkey Therapeutics offers the Locksmith® computational platform, which maps synergistic pharmacology across 4,000 approved drugs, 10,000 biological pathways, and 600 billion genetic variants to identify therapeutic drug combinations for complex diseases. The company partners with pharmaceutical and biotech companies through Subscribe, Unlock, and Advance engagement pathways, enabling combinations of approved drugs to bypass traditional preclinical development and proceed directly to human proof of concept. Passkey is preparing for clinical trials in 4 indications.
Is Passkey a public or private company?
Passkey is a private company. It is classified as venture growth investor backed and is currently operating.
When was Passkey founded?
Passkey was founded in 2022. It employs 1 to 10 people.
Where is Passkey based?
Passkey is headquartered in Cambridge, United States, in the North America region.
How does Passkey make money?
Three revenue lines are on record. Access Fee Partnership is the primary driver. The others are clinic-Ready Combination Licensing and clinical and Commercial Outcomes.
Who are Passkey's main competitors?
Direct peers on record are Insitro, Recursion Pharmaceuticals, Schrödinger, Exscientia, Atomwise, Isomorphic Labs and Healx. Emerging players are Dewpoint Therapeutics and Lantern Pharma. Owkin is listed as a broad incumbent.
Does Passkey have an API?
No public API is recorded for Passkey.
What industry is Passkey in?
Passkey's product category is Computational Drug Discovery. Its primary akta.pro industry code is HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 325412 and its SIC code is 8000.